logo

Redhill Biopharma Ltd. (RDHL)



Trade RDHL now with
  Date
  Headline
2/23/2021 7:16:24 AM RedHill Biopharma Plans To Expand Phase 2/3 Study Of Opaganib In Patients With Severe COVID-19 To The U.S.
2/18/2021 7:14:27 AM RedHill Biopharma, Cosmo Pharma Sign Manufacturing Agreements For Movantik And RHB-204
2/17/2021 7:22:10 AM RedHill Biopharma Says First Patient Dosed In U.S. Phase 2/3 COVID-19 Outpatient Study With RHB-107
1/28/2021 7:31:48 AM RedHill Biopharma Announces Manufacturing Deal With Cosmo Pharma To Further Expand Manufacturing Capacity For Opaganib
1/12/2021 9:01:56 AM RedHill Biopharma Raises Previously Announced Bought Deal To $25 Mln
1/11/2021 7:14:27 AM RedHill's Partner Cosmo Pharma Completes Phase 2 Study Of Rifamycin SV-MMX 600mg In IBS-D
1/6/2021 7:11:40 AM RedHill's RHB-204 Granted FDA Fast Track Designation For NTM Disease
12/31/2020 9:33:53 AM RedHill Biopharma Reports Preliminary Top-line Data From U.S. Phase 2 Study With Orally-administered Opaganib
12/22/2020 7:11:12 AM RedHill's Phase 2/3 COVID-19 Study Of Opaganib Passes Second DSMB With Unanimous Recommendation To Continue
12/15/2020 9:32:04 AM RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting In Preclinical Model
12/7/2020 7:22:55 AM RedHill Biopharma Extends Talicia Unrestricted National And Regional Commercial Coverage To Over 40 Mln Addl Americans